Herantis Pharma opening recruitment in Parkinson's disease study in Helsinki and Lund based on favorable first CDNF safety assessment
Herantis Pharma opening recruitment in Parkinson's disease study in Helsinki and Lund based on favorable first CDNF safety assessment Herantis Pharma PlcCompany release 14 February 2018 at 9:00 am Herantis Pharma Plc's ("Herantis") first-in-human clinical study with the company's investigational product CDNF for the treatment of Parkinson's disease has proceeded to its first CDNF safety assessment by an independent Data Safety Monitoring Board ("DSMB"). Following the DSMB's recommendation based on safety data on the first patients, the study continues as planned. Subsequently